Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
We are conducting an open-label multicentre phase II study to evaluate the efficacy and safety of the combination therapy of XELOX and bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer. The primary endpoint of the study is progression-free survival. The secondary endpoints are the toxicity, overall response rate, time to treatment failure and overall survival. Thirty-five patients are required for the study.
Oba
Koji
K
Translational Research and Clinical Trial Center, Hokkaido University Hospital, Hokkaido University, Sapporo, Japan. k.oba@huhp.hokudai.ac.jp
Matsuoka
Masaki
M
Satoh
Taroh
T
Muro
Kei
K
Oriuchi
Noboru
N
Sakamoto
Junichi
J
Mishima
Hideyuki
H
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D010071:Oxaloacetates; D018579:Patient Selection; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil